Live feed
·
INSIDERFilingvia Quantisnow
4D Molecular Therapeutics Inc. logo

4D Molecular Therapeutics (FDMT) COO Kamal received 178,400 Stock Option (Right to Buy)

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Insider transactions reported

Fariborz Kamal (President & COO at 4D Molecular Therapeutics Inc., FDMT) reported that they received 178,400 Stock Option (Right to Buy) on Mar 6, 2025.

Reporting person
Kamal Fariborz
Role
President & COO

Options and other derivatives

Options and other derivative transactions
DateTypeSecuritySharesPriceValueHeld after
Mar 6, 2025Grant or award (A)Stock Option (Right to Buy)On 178,400 Common Stock1+178,400--178,400 direct

Holdings before and after

  • Stock Option (Right to Buy): 0 to 178,400 direct

Footnotes from the filing

  1. 1. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the Vesting Commencement Date ), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Transaction codes in this filing

Grant or award:
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ

What did Kamal report in this FDMT Form 4?

Fariborz Kamal (President & COO at 4D Molecular Therapeutics Inc., FDMT) reported that they received 178,400 Stock Option (Right to Buy) on Mar 6, 2025.

What does transaction code A mean on an SEC Form 4?

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

Historical context for FDMT

Earlier insider filings at FDMT

Quantisnow market dataNASDAQ
4D Molecular Therapeutics Inc. logo
FDMT
4D Molecular Therapeutics Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Listed since
2020
Get push alerts for FDMT

Follow FDMT and get a push notification the moment its next story breaks.

Full FDMT profile on Quantisnow
Original source Picked up and delivered by Quantisnow in real time

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FDMT (4D Molecular Therapeutics Inc.) and more on Quantisnow.